Compare Mesoblast Limited (MESO) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs NIO Inc. — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while NIO Inc. trades at $4.81 (market cap $12.55B). The key difference: NIO Inc. is far larger — about 5.8× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals.
| MESO | NIO | |
|---|---|---|
Market Cap | $2.17B | $12.55B |
Sector | Technology | Consumer Cyclical |
52-Week High | $20.96 | $7.89 |
52-Week Low | $12.88 | $4.44 |
Enterprise Value | $2.17B | $11.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
NIO trades at $4.83, down 1.02% on the day, with a bearish technical signal from moving averages. Revenue grew to $87.49B in 2025, but the company posted a net loss of $15.57B, reflecting persistent profitability challenges. Recent news highlights strong Q2 2026 vehicle deliveries, up 49.4% year-over-year, and a Goldman Sachs upgrade to Buy with a $7 price target, suggesting potential upside.
The outlook remains mixed: delivery growth and analyst optimism contrast with deep losses and negative cash flow. Key risks include intense EV competition and reliance on financing. Investors should weigh the growth trajectory against the path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
